ATYR 1923

Drug Profile

ATYR 1923

Alternative Names: ATYR1923; iMod.Fc; Stalaris

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator aTyr Pharma
  • Class Antifibrotics; Proteins; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Interstitial lung diseases
  • Preclinical Pneumonia; Pulmonary fibrosis

Most Recent Events

  • 27 Nov 2017 Phase-I clinical trials in Interstitial lung diseases (In volunteers) in Australia (IV) (ACTRN12617001446358p)
  • 14 Aug 2017 aTyr Pharma plans a phase I trial for Interstitial lung diseases (In volunteers) in late 2017
  • 16 Mar 2017 Preclinical trials in Interstitial lung diseases in USA, before March 2017 (aTyr Pharma Form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top